TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map
BOSTON, May 17, 2013 /PRNewswire/ — TechAtlas Group has announced the release of the latest update for their competitive landscape map for the Chronic Kidney Disease (CKD) market. This particular landscape highlights over 90 international companies with drugs and devices currently on the market and in development addressing CKD and its sequelae.
- hypertension – renal denervation
- diabetic nephropathy – antifibrotics
- glomerular nephritis – biologics targeting immune complexes
- polycystic kidney disease – small molecule inhibitors
- anemia – hepcidin inhibitors
- hyperkalemia – safer agents
- mineral and bone disease – cost saving strategies
TechAtlas’ analysts have evaluated each technology according to the parameters that dictate their commercial competitiveness, including benefit/risk, cost, convenience, and reimbursement dynamics (e.g., exposure to bundling). For example, non-calcium-based phosphate binders will compete on price as oral drugs enter the dialysis bundle, but certain iron-based agents will have an advantage since they also reduce the need for expensive anemia drugs. Among future anemia agents, injectable antibodies and RNAi targeting hepcidin will have different times to onset of action, and both will compete against the more convenient oral HIF-PH inhibitors. However, all of these anemia therapies will face pricing pressure in a bundled dialysis environment and will be better received for treating anemia in pre-dialysis patients but only in certain geographies.
The TechAtlas map graphically presents every CKD-related technology, old and new, in its proper context to clearly show the relationship of competing and complementary products for specific unmet needs. This map was built on extensive primary research, including interviews with companies, investors, key opinion leaders in the nephrology community, academic researchers, technical experts, consumers of technologies, and other stakeholders in the field, as well as an exhaustive review of public and proprietary resources.
TechAtlas Group’s current subscribers have reported that their researchers, BD analysts, and executives have used it to guide their business development efforts, R&D resource allocation, and competitive intelligence.
Some of the 90+ companies featured on the TechAtlas Chronic Kidney Disease landscape include: AbbVie, Amgen, Astellas, FibroGen, Fresenius, Johnson & Johnson, Keryx, and ZS Pharma.
For further information on obtaining a copy of this report through an annual subscription, please consult our website:
About TechAtlas Group
TechAtlas Group, LLC brings a novel, multi-dimensional, visually stimulating approach to decision makers who are already flooded with data and information but are seeking context and actionable insight to guide their resource allocation for R&D and commercial activities. Founded in 2011, TechAtlas Group, LLC is headquartered in Boston, MA. Their large team of PhDs is trained to analyze the viability and commercial competitiveness of a variety of technologies and distill their insights into a visual landscape. As each field evolves, the maps are updated and issued to subscribers. Their mission is to convey in one dynamic diagram what has conventionally been crammed into a static 100-page report.
SOURCE TechAtlas Group